Morgan Stanley’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-15,319
| Closed | -$3K | – | 6996 |
|
|
2018
Q1 | $3K | Buy |
15,319
+4,944
| +48% | +$968 | ﹤0.01% | 6485 |
|
|
2017
Q4 | $14K | Sell |
10,375
-18,859
| -65% | -$25.4K | ﹤0.01% | 6169 |
|
|
2017
Q3 | $62K | Buy |
29,234
+4,121
| +16% | +$8.74K | ﹤0.01% | 5720 |
|
|
2017
Q2 | $72K | Sell |
25,113
-13,342
| -35% | -$38.3K | ﹤0.01% | 5755 |
|
|
2017
Q1 | $131K | Buy |
38,455
+2,047
| +6% | +$6.97K | ﹤0.01% | 5502 |
|
|
2016
Q4 | $63K | Sell |
36,408
-352,694
| -91% | -$610K | ﹤0.01% | 5692 |
|
|
2016
Q3 | $1.29M | Buy |
389,102
+52,783
| +16% | +$175K | ﹤0.01% | 3837 |
|
|
2016
Q2 | $1.45M | Sell |
336,319
-72,456
| -18% | -$312K | ﹤0.01% | 3687 |
|
|
2016
Q1 | $2.3M | Buy |
408,775
+78,598
| +24% | +$442K | ﹤0.01% | 3238 |
|
|
2015
Q4 | $5.68M | Sell |
330,177
-67,787
| -17% | -$1.17M | ﹤0.01% | 2546 |
|
|
2015
Q3 | $8.4M | Buy |
397,964
+110,605
| +38% | +$2.33M | ﹤0.01% | 2142 |
|
|
2015
Q2 | $14.2M | Sell |
287,359
-4,136
| -1% | -$205K | ﹤0.01% | 1785 |
|
|
2015
Q1 | $22.8M | Buy |
291,495
+60,763
| +26% | +$4.76M | 0.01% | 1354 |
|
|
2014
Q4 | $14M | Buy |
230,732
+105,338
| +84% | +$6.38M | 0.01% | 1761 |
|
|
2014
Q3 | $5.34M | Buy |
125,394
+116,626
| +1,330% | +$4.97M | ﹤0.01% | 2588 |
|
|
2014
Q2 | $542K | Buy |
8,768
+3,351
| +62% | +$207K | ﹤0.01% | 4520 |
|
|
2014
Q1 | $352K | Buy |
5,417
+3,174
| +142% | +$206K | ﹤0.01% | 4793 |
|
|
2013
Q4 | $127K | Sell |
2,243
-1,008
| -31% | -$57.1K | ﹤0.01% | 5253 |
|
|
2013
Q3 | $200K | Sell |
3,251
-1,522
| -32% | -$93.6K | ﹤0.01% | 4890 |
|
|
2013
Q2 | $279K | Buy |
+4,773
| New | +$279K | ﹤0.01% | 4645 |
|